Tue, February 14, 2012
Mon, February 13, 2012
Sun, February 12, 2012
Fri, February 10, 2012
Thu, February 9, 2012
Wed, February 8, 2012
[ Wed, Feb 08th 2012 ] - Market Wire
Imaging3 Updates Website
Tue, February 7, 2012
Mon, February 6, 2012
Sun, February 5, 2012
[ Sun, Feb 05th 2012 ] - Market Wire
30 a.m. ET
Sat, February 4, 2012
Fri, February 3, 2012
Thu, February 2, 2012
Wed, February 1, 2012

MAP Pharmaceuticals to Present at Upcoming Investor Conferences


//health-fitness.news-articles.net/content/2012/ .. to-present-at-upcoming-investor-conferences.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


MAP Pharmaceuticals to Present at Upcoming Investor Conferences -- id='temp_ReleaseStart'>MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ --

MAP Pharmaceuticals to Present at Upcoming Investor Conferences

[ ]

MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: [ MAPP ]) today announced that the Company will participate in the following investor conferences in February 2012:

Leerink Swann 2012 Global Healthcare Conference
Thursday, February 16, at 11:30 a.m. ET in New York

2012 Citi Global Healthcare Conference
Tuesday, February 28, at 8:00 a.m. ET in New York

A live webcast of each event will be available on the Investor Relations section of MAP Pharmaceuticals' website at [ http://www.mappharma.com ]. A replay also will be available within 24 hours for seven days following each presentation.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology.  The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The New Drug Application for LEVADEX is currently under review by the U.S. Food and Drug Administration.  MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at [ http://www.mappharma.com ].

CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
[ lborland@mappharma.com ]

SOURCE MAP Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.mappharma.com ]


Publication Contributing Sources